Literature DB >> 17331160

Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.

Masato Yoneda1, Tomoyuki Iwasaki, Koji Fujita, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Shiro Maeyama, Koichiro Wada, Satoru Saito, Yasuo Terauchi, Atsushi Nakajima.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury. The spectrum of NAFLD is broad, extending from simple steatosis through nonalcoholic steatohepatitis (NASH). Insulin resistance has been found to increase the risk of NASH, and obesity, and decreased levels of adiponectin are important factors in determining the severity of insulin resistance. Recent evidence has indicated that hypoadiponectinemia is involved in hepatic steatosis and NASH.
METHODS: To investigate whether hypoadiponectinemia causes hepatic steatosis in type 2 diabetes mellitus (DM) patients independently of visceral adipose tissue, we measured the plasma adiponectin concentration, hepatic fat content based on the liver-to-spleen ratio (L/S ratio) according to computed tomography (CT) attenuation values, and the amount of visceral adipose tissue and subcutaneous adipose tissue by CT in 248 type 2 DM patients. We also investigated the relationship between the serum level of adiponectin and hepatic fibrosis.
RESULTS: Significant correlations were observed between the L/S ratios and aspartate aminotransferase, alanine aminotransferase, visceral adipose tissue, subcutaneous adipose tissue, and serum adiponectin values (r=0.300, p=0.0007), and there was a highly significant inverse correlation between the visceral adipose tissue values and the serum adiponectin levels (r=-0.327, p<0.0002). The subcutaneous adipose tissue values, however, were not correlated with the serum adiponectin levels. Multiple regression analysis was used to quantify the impact of measured variables on the L/S ratio. After adjustment for age, gender, and visceral adipose tissue, the serum adiponectin levels were still significantly correlated with the L/S ratios (p=0.0064). And there was a stepwise decrease in the serum adiponectin in parallel to the severity of hepatic fibrosis.
CONCLUSIONS: Hypoadiponectinemia is concluded to be involved in the etiology of hepatic steatosis independently of visceral adipose tissue content, and is considered to be an important factor in the progression of fibrosis; further studies will be necessary to elucidate the exact physiological role of adiponectin and its contribution to the progression of NASH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331160     DOI: 10.1111/j.1530-0277.2006.00281.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  16 in total

1.  Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury.

Authors:  Mingyan Zhou; Aimin Xu; Paul K H Tam; Karen S L Lam; Lawrence Chan; Ruby L C Hoo; Jing Liu; Kim H M Chow; Yu Wang
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

2.  Adiponectin regulation of stellate cell activation via PPARγ-dependent and -independent mechanisms.

Authors:  Mahnoush S Shafiei; Shoba Shetty; Philipp E Scherer; Don C Rockey
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

3.  Enhanced fatty acid flux triggered by adiponectin overexpression.

Authors:  Shoba Shetty; Maria A Ramos-Roman; You-Ree Cho; Jonathan Brown; Jorge Plutzky; Eric S Muise; Jay D Horton; Philipp E Scherer; Elizabeth J Parks
Journal:  Endocrinology       Date:  2011-11-01       Impact factor: 4.736

4.  Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver.

Authors:  Pil-Hoon Park; Carlos Sanz-Garcia; Laura E Nagy
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

5.  The prevalence and predictors of active brown adipose tissue in Chinese adults.

Authors:  Zhaoyun Zhang; Aaron M Cypess; Qing Miao; Hongying Ye; Chong Wee Liew; Qiongyue Zhang; Ruidan Xue; Shuo Zhang; Chuantao Zuo; Zhensheng Xu; Qiqun Tang; Renming Hu; Yihui Guan; Yiming Li
Journal:  Eur J Endocrinol       Date:  2014-02-04       Impact factor: 6.664

6.  Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.

Authors:  Marianna Argentou; Dina G Tiniakos; Menelaos Karanikolas; Maria Melachrinou; Maria G Makri; Christos Kittas; Fotis Kalfarentzos
Journal:  Obes Surg       Date:  2009-07-15       Impact factor: 4.129

7.  Preliminary report: hepatic fat and inflammation in type 2 diabetes mellitus.

Authors:  Aramesh Saremi; Matthew Allison; Dominic Ditomasso; Ling Ge; Robert Anderson; Tom E Moritz; William Duckworth; Carlos Abraira; Peter D Reaven
Journal:  Metabolism       Date:  2009-10-21       Impact factor: 8.694

8.  A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.

Authors:  P Matafome; E Nunes; T Louro; C Amaral; J Crisóstomo; L Rodrigues; A R Moedas; P Monteiro; A Cipriano; R Seiça
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-21       Impact factor: 3.000

9.  Expansion of Bone Marrow Adipose Tissue During Caloric Restriction Is Associated With Increased Circulating Glucocorticoids and Not With Hypoleptinemia.

Authors:  William P Cawthorn; Erica L Scheller; Sebastian D Parlee; H An Pham; Brian S Learman; Catherine M H Redshaw; Richard J Sulston; Aaron A Burr; Arun K Das; Becky R Simon; Hiroyuki Mori; Adam J Bree; Benjamin Schell; Venkatesh Krishnan; Ormond A MacDougald
Journal:  Endocrinology       Date:  2015-12-22       Impact factor: 4.736

10.  Prevalence of non-alcoholic fatty liver disease and its relation to hypoadiponectinaemia in the middle-aged and elderly Chinese population.

Authors:  Zhen Yang; Xuanchun Wang; Jie Wen; Zi Ye; Qin Li; Min He; Bin Lu; Charlotte Ling; Songhua Wu; Renming Hu
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.